Epcoritamab + Epcoritamab, lenalidomide and rituximab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Large B-cell Lymphoma
Conditions
Relapsed/Refractory Large B-cell Lymphoma
Trial Timeline
May 14, 2024 → May 1, 2028
NCT ID
NCT06414148About Epcoritamab + Epcoritamab, lenalidomide and rituximab
Epcoritamab + Epcoritamab, lenalidomide and rituximab is a phase 2 stage product being developed by AbbVie for Relapsed/Refractory Large B-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06414148. Target conditions include Relapsed/Refractory Large B-cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06414148 | Phase 2 | Recruiting |
Competing Products
20 competing products in Relapsed/Refractory Large B-cell Lymphoma